Last reviewed · How we verify
Chidamide+ Fulvestrant
Chidamide+ Fulvestrant is a HDAC inhibitor + selective estrogen receptor degrader (combination therapy) Small molecule drug developed by Liaoning Cancer Hospital & Institute. It is currently FDA-approved for Estrogen receptor-positive, HER2-negative breast cancer.
Chidamide inhibits histone deacetylases to reactivate tumor suppressor genes, while fulvestrant blocks estrogen receptor signaling to inhibit hormone-dependent breast cancer growth.
Chidamide is a small molecule used in targeted therapy for breast cancer. It is being studied in combination with Fulvestrant for the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
At a glance
| Generic name | Chidamide+ Fulvestrant |
|---|---|
| Sponsor | Liaoning Cancer Hospital & Institute |
| Drug class | HDAC inhibitor + selective estrogen receptor degrader (combination therapy) |
| Target | Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Chidamide is a histone deacetylase (HDAC) inhibitor that promotes acetylation of histones, leading to chromatin remodeling and reactivation of silenced tumor suppressor genes. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, eliminating estrogen-dependent signaling. The combination targets both epigenetic regulation and hormone-driven proliferation in estrogen receptor-positive breast cancer.
Approved indications
- Estrogen receptor-positive, HER2-negative breast cancer
Common side effects
- Thrombocytopenia
- Nausea
- Fatigue
- Diarrhea
- Hot flashes
Key clinical trials
- Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer (PHASE2)
- Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (PHASE2)
- A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy (NA)
- Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer (PHASE2)
- Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy (PHASE2)
- Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. (PHASE2)
- An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer (PHASE2)
- Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chidamide+ Fulvestrant CI brief — competitive landscape report
- Chidamide+ Fulvestrant updates RSS · CI watch RSS
- Liaoning Cancer Hospital & Institute portfolio CI
Frequently asked questions about Chidamide+ Fulvestrant
What is Chidamide+ Fulvestrant?
How does Chidamide+ Fulvestrant work?
What is Chidamide+ Fulvestrant used for?
Who makes Chidamide+ Fulvestrant?
What drug class is Chidamide+ Fulvestrant in?
What development phase is Chidamide+ Fulvestrant in?
What are the side effects of Chidamide+ Fulvestrant?
What does Chidamide+ Fulvestrant target?
Related
- Drug class: All HDAC inhibitor + selective estrogen receptor degrader (combination therapy) drugs
- Target: All drugs targeting Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα)
- Manufacturer: Liaoning Cancer Hospital & Institute — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Estrogen receptor-positive, HER2-negative breast cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing